SCHEMBL16615516

SCHEMBL16615516

CCC(C(=O)Nc1ccc(S(=O)(=O)NC(C)(C)C)cc1)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.65
LMNA P02545 2/20 0.65
HTT P42858 2/20 0.65
MEN1 O00255 1/20 0.65
CYP3A4 P08684 1/20 0.65
CYP2D6 P10635 1/20 0.65
MAPT P10636 1/20 0.65
CYP2C9 P11712 1/20 0.65
PKM P14618 1/20 0.65
CNR1 P21554 1/20 0.65
CYP2C19 P33261 1/20 0.65
KMT2A Q03164 1/20 0.65
GPR55 Q9Y2T6 1/20 0.65
ALDH1A1 P00352 2/20 0.62
CRHBP P24387 2/20 0.61
CRHR2 Q13324 2/20 0.61
HDAC3 O15379 3/20 0.57
HDAC4 P56524 3/20 0.57
HDAC1 Q13547 3/20 0.57
HDAC7 Q8WUI4 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615822 0.85 ALDH1A1 (0.66) SMN1; SMN2LMNAHTTMEN1MAPT
SCHEMBL16615850 0.84 SCN3A (0.65) SMN1; SMN2LMNAHTTALDH1A1CRHBP
SCHEMBL16615530 0.84 ALDH1A1 (0.70) SMN1; SMN2LMNAHTTMAPTCNR1
SCHEMBL16615489 0.83 LMNA (0.70) SMN1; SMN2LMNAHTTMEN1MAPT
SCHEMBL9138268 0.82 ALDH1A1 (0.68) SMN1; SMN2LMNAHTTMEN1MAPT
SCHEMBL16615514 0.81 L3MBTL1 (0.62) SMN1; SMN2LMNAHTTMEN1MAPT
SCHEMBL16615791 0.80 ALDH1A1 (0.65) SMN1; SMN2LMNAHTTMEN1MAPT
SCHEMBL7752354 0.80 ALDH1A1 (0.82) SMN1; SMN2LMNAHTTMEN1CYP3A4
SCHEMBL19074542 0.80 ALDH1A1 (0.82) SMN1; SMN2LMNAHTTMEN1CYP3A4
SCHEMBL8130545 0.79 MEN1 (0.51) SMN1; SMN2LMNAHTTMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF Université de Montréal (CA) 2016-07-28 US disclosed
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF Université de Montréal (CA) 2016-07-28 US disclosed
WO-2015042685-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF VALORISATION-RECHERCHE (CA) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF FBL, HNRNPA1, HNRNPUL1 SMN1; SMN2 81/4885LMNA 705/4885HTT 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.